Adaptive Biotechnologies Stock Rises Nearly 6% on Strong Q2 Earnings

Adaptive Biotechnologies (ADPT) saw its shares climb nearly 6% following the release of its second-quarter earnings, outperforming the broader market's modest 0.7% gain. The biotech firm reported revenue of $58.9 million, a 36% year-over-year increase, driven largely by its minimal residual disease (MRD) business, which accounted for 85% of total revenue.

The company's net loss narrowed to $25.6 million ($0.17 per share), significantly better than the $46 million loss in the same quarter last year. Adaptive also surpassed analyst expectations, which had projected revenue of $49 million and a net loss of $0.24 per share.

Buoyed by strong MRD performance, Adaptive raised its full-year revenue guidance for the segment to $190 million-$200 million, signaling confidence in continued growth. The stock's rally reflects investor Optimism around the company's expanding role in cancer diagnostics and treatment monitoring.